Furthermore, we found no evidence linking PCSK9 inhibitors to bladder, thyroid, pancreatic, colorectal cancers, kidney malignancies (excluding renal pelvis tumors), brain, or esophageal cancers, reinforcing the non-association of PCSK9 with these seven types of cancer. This evidence concerns the gene PCSK9 and renal pelvis neoplasm.